CHMP gives thumbs up for Bydureon
This article was originally published in Scrip
Executive Summary
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval in the European Union for once-weekly Bydureon (exenatide) 2mg in combination with certain oral therapies to improve glycemic control in adults with Type II diabetes who have not achieved adequate glycemic control on maximally tolerated doses of other drugs.